The Microfluidic Immunoassay Market is projected to reach $1.59 billion by 2031 at a CAGR of 7.3% from 2024 to 2031. The growth of this market is driven by the increasing use of microfluidic immunoassays in drug discovery & development and biomarker detection, the advantages of lab-on-chip immunoassays over conventional immunoassays, pharmaceutical & biotechnology companies’ increasing focus on research & development, and the miniaturization of biological and chemical assays. Moreover, the increasing demand for point-of-care diagnostics and recent advancements in microfluidic immunoassay technology are expected to generate market growth opportunities.
Pharmaceutical and biotechnology companies allocate significant resources to research. Microfluidic immunoassay is majorly used for the detection of biomarkers associated with diseases for understanding disease mechanism for drug development and disease detection. Microfluidic immunoassays have become increasingly important in maintaining precision and accuracy in drug research & development and reducing the time required for research.
Numerous drug discovery processes can benefit from the use of microfluidics, including drug compound synthesis, screening, delivery, and the development of carrier systems. Microfluidic immunoassays have applications in drug screening due to their benefits, such as improved throughput, reduced consumption of reagents, automation, reduced reaction time, seamless integration and parallelization, simplification of operational steps, and reduced waste generation.
Pharmaceutical and biotechnology companies combine microfluidic immunoassays with various detection technologies for high-throughput screening and the detection and mechanistic study of drugs. The players operating in this market are collaborating to develop advanced microfluidic immunoassay products.
Click here to: Get Free Sample Pages of this Report
Microfluidics sector is gaining traction in recent years owing to the ongoing research in the field and increasing applications in drug discovery and diagnostics. The key players operating in the market and government agencies are providing funding and grants for the research.
In many cases, a single molecular event is inadequate to indicate the pathophysiology of diseases such as cancer. The adoption of multiplexed diagnostic testing has increased due to its benefits, such as reduced reagent consumption, multiple analyte detection, improved sensitivity, and shorter reaction time. Therefore, microfluidic detection of multiple analytes in a single test has become a growing trend. Many companies are developing multiple-analyte tests to expand their LOC portfolios. POC-based multi-analyte testing for infectious microorganisms could be useful in diagnosing diseases and initiating treatment, as getting results for a laboratory culture-based analysis would be time-consuming, and a single parametric test may not provide accurate diagnosis. A single lab-on-chip device enabling the diagnosis of the most common sexually transmitted diseases in a single run can save time and money.
Microfluidics technology integrates entire lab procedures on a single chip. Therefore, the technology has generated significant interest in recent years, mainly due to the reduced requirement of cumbersome instruments. Lab-on-chip technology has evolved over nearly two decades, with various materials used in the design and manufacture of the devices. Paper is gaining much traction as the material of choice for manufacturing microfluidics based POC cartridges, mainly due to the advantages of paper, such as low costs and affordability, compatibility with several medical applications, and ability to transport fluid (through capillary forces) without needing any external forces. Presently, both industry and academia are focused on research into paper-based microfluidics. The study published in 2022, presents the development of a paper-based microfluidic device capable of remote biofluid collection, followed by an analysis of the dried clinical samples using a miniature mass spectrometer. The stability and sensitivity of the developed paper-based immunoassay platform would allow miniature mass spectrometers to be used for point-of-care malaria detection as well as in large-scale surveillance screening to aid eradication programs.
Existing laboratory diagnostic technologies require sophisticated infrastructure, expensive reagents, stable electricity supply, long assay times, and trained staff. Also, laboratories and medical testing facilities are often limited and inaccessible to patients in remote areas. Hence, developing countries are increasingly facing the burden of infectious and non-communicable diseases, leading to high mortality. According to the WHO, globally, an estimated 1 billion cases of influenza are registered annually, with 3-5 million being severe cases. Deploying rapid and easy-to-use POC tests and microfluidics based POC tests in low-income countries can enable enhanced disease diagnosis on-site without the need for trained healthcare professionals.
Moreover, laboratory testing requires a significant amount of time and reagent consumption. For instance, urinalysis at a laboratory/medical testing facility takes 24–48 hours to deliver results. This time can be reduced considerably with the use of lab-on-chip POC tests. Thus, manufacturers of POC diagnostics, including microfluidic immunoassays, can expand to untapped markets in developing countries to leverage these opportunities.
Based on product, the microfluidic immunoassay market is segmented into consumables and systems. In 2024, the consumables segment is expected to account for the largest share of 69.6% of the microfluidic immunoassay market. The consumables segment is further segmented into microfluidic cartridges and reagents. The microfluidic cartridges segment is expected to account for the largest share. Cartridges have become essential tools for diagnosing various diseases. These assays are used for testing infectious diseases, cancer markers, cytokines, cardiac markers, autoimmune diseases, and endocrine diseases. Their increasing application areas in clinical diagnostics and R&D are driving the market's growth.
Based on technology, the microfluidic immunoassay market is segmented into electrochemical detection and optical detection. In 2024, the electrochemical detection segment is expected to account for the largest share of the microfluidic immunoassay market. Electrochemical detection has been widely employed in point-of-care testing owing to its cost efficiency, ability to analyze turbid samples, and adaptability for miniaturization. Electrochemical detection coupled with microfluidics is a promising detection technology for immunoassays owing to the benefits such as simple and portable assay, low sample consumption, low detection limit, and rapid method contributing to the largest share of the segment.
Based on application, the global microfluidic immunoassay market is segmented into cardiology, infectious diseases, oncology, and other applications. In 2024, the cardiology segment is expected to account for the largest share of 53.5% of the microfluidic immunoassay market. Cardiac markers are released in the blood after injury to the heart muscles. These indicators are used as a measure to diagnose cardiovascular diseases. The rising prevalence of cardiovascular diseases is increasing the demand for microfluidic immunoassay detection kits. According to, American Heart Association (U.S.), a non-profit organization involved in consumer education about cardiovascular disease, more than 350,000 cardiac arrests occur outside the hospital each year. The microfluidic cartridges detects cardiac biomarkers for accurate diagnosis. The microfluidic cardiac biomarker tests are also used in the biomedical and clinical research. These biomarkers are objectively measured and used to indicate a certain biological state, whether physiological, pathological, or pharmacological, and gather information about normal molecular physiology as well as cardiovascular disease (CVD) activity and progression, which can further be used in drug discovery is further supporting the largest share of segment.
The oncology segment is expected to grow at the highest CAGR of 8.7% during the forecast period. The increasing prevalence of cancer (malignant tumor) and the development of microfluidic devices for the analysis of various biomarkers, including proteins, circulating tumor cells, exosomes, and cell-free DNA, contributed to the highest CAGR of the segment. For instance, cancer is a major health concern globally and is one of the leading causes of morbidity and mortality across the world. According to GLOBOCAN, the global burden of cancer is expected to increase from 19.3 million cases in 2020 to 24.6 million cases by 2030.
Based on end user, the microfluidic immunoassay market is segmented into pharmaceutical & biotechnology companies, diagnostic laboratories, hospitals, and other end users. In 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the market. The rising number of research laboratories, increasing investment in R&D, and rising funding for research laboratories support the largest share of the market. The funding for research laboratories is increasing due to the increasing demand for new drugs and therapies.
In 2024, North America is expected to account for the largest share of the 40.3% of microfluidic immunoassay market. The largest share of the region is attributed to rising government support and spending for research activities, rising R&D investment by pharmaceutical & biopharmaceutical companies, high number of laboratory tests performed annually, developed healthcare infrastructure in the region, the growing trend for self-testing, a high number of CLIA-waived tests, and increasing prevalence of chronic diseases. according to the WHO, new cancer cases in the U.S. are expected to increase from 2.2 million in 2020 to 2.7 million by 2030. Microfluidic immunoassays have a major application in cancer diagnosis and targeted therapy based on biomarkers. Therefore, the increasing prevalence of cancer is expected to propel the growth of the microfluidic immunoassay market in the region.
Moreover, the market in Asia-Pacific is slated to register the highest growth rate of 9.1% during the forecast period. The growth of the microfluidic immunoassay market in Asia-Pacific is attributed to the rising research funding in the healthcare and pharmaceutical industry, the rising number of research laboratories, the advancing research framework, and the growing number of diagnostic laboratories in countries such as China, India, Japan, South Korea, and others. For instance, in 2022, the R&D spending of BeiGene Ltd. (China), one of the major pharmaceutical companies, increased by 12.4% from 2021. The increasing use of microfluidic immunoassay in precision medicine and government initiatives for precision medicine is also driving the market growth.
The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years (2021–2024). The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years (2021–2024). The key players operating in the global microfluidic immunoassay market are Becton, Dickinson and Company (U.S.), Revvity, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Nanomix Corporation (U.S.), Micropoint Biotechnologies Co., Ltd. (China), Biosurfit SA (Portugal), Koninklijke Philips N.V. (Netherland), NanoEnTek Inc. (South Korea), and QuidelOrtho Corporation (U.S.).
|
Particulars |
Details |
|
Number of Pages |
259 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
7.3% |
|
Estimated Market Size (Value) |
$1.59 billion by 2031 |
|
Segments Covered |
By Product
By Technology
By Application
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America, and Middle East & Africa |
|
Key Companies |
The key players operating in the global microfluidic immunoassay market are Becton, Dickinson and Company (U.S.), Revvity, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Nanomix Corporation (U.S.), Micropoint Biotechnologies Co., Ltd. (China), Biosurfit SA (Portugal), Koninklijke Philips N.V. (Netherland), NanoEnTek Inc. (South Korea), and QuidelOrtho Corporation (U.S.). |
The global microfluidic immunoassay market covers the study of various microfluidic immunoassay cartridges, reagents, and systems used in various application areas at the regional and country levels. The report also provides insights on factors impacting market growth, regulatory analysis, pricing analysis, and Porter’s five forces analysis.
The global microfluidic immunoassay market is projected to reach $1.59 billion by 2031 at a CAGR of 7.3% during the forecast period.
Among the products, the consumables segment is expected to hold a major market share of 69.6% of the microfluidic immunoassay market in 2024. The largest market share is attributed to the reduced manual errors with the use of microfluidic cartridges, integration of several tests on a single cartridge, rapid reaction time, integration of lab procedures on a single device, higher analytical sensitivity, portability, improved temperature control, and easier parallelization and automation.
The growth of this market is attributed to several factors; the growth of this market is driven by the increasing use of microfluidic immunoassays in drug discovery & development and biomarker detection, the advantages of lab-on-chip immunoassays over conventional immunoassays, pharmaceutical & biotechnology companies’ increasing focus on research & development, and the miniaturization of biological and chemical assays.
The key players operating in the global microfluidic immunoassay market are Becton, Dickinson and Company (U.S.), Revvity, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Nanomix Corporation (U.S.), Micropoint Biotechnologies Co., Ltd. (China), Biosurfit SA (Portugal), Koninklijke Philips N.V. (Netherland), NanoEnTek Inc. (South Korea), and QuidelOrtho Corporation (U.S.).
The growth of the microfluidic immunoassay market in Asia-Pacific is attributed to the rising research funding in the healthcare and pharmaceutical industry, the rising number of research laboratories, the advancing research framework, and the growing number of diagnostic laboratories in countries such as China, India, Japan, South Korea, and others. For instance, in 2022, the R&D spending of BeiGene Ltd. (China), one of the major pharmaceutical companies, increased by 12.4% from 2021.
This report provides pre & post COVID-19 market estimates.
1 Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4 Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Impact Analysis of Market Dynamics
4.2.1.1. Increasing Use of Microfluidic Immunoassays in Drug Discovery & Development and Biomarker Detection Driving Market Growth
4.2.1.2. Bubble Formation and Dead Volume Limiting the Adoption of Microfluidics Devices
4.2.1.3. Increasing Demand for Point-of-Care Testing Generating Growth Opportunities for Market Players
4.2.1.4. Selecting Suitable Substrate Materials to Design Microfluidic Chips to Remain a Major Challenge for Market Players
4.2.2. Factor Analysis
4.3. Technology Trends
4.3.1. Multiplexed Panel Detection
4.3.2. Paper-Based Microfluidics
4.4. Regulatory Analysis
4.4.1. North America
4.4.1.1. U.S.
4.4.1.2. Canada
4.4.2. Europe
4.4.3. Asia-Pacific
4.4.3.1. China
4.4.3.2. Japan
4.4.3.3. India
4.4.4. Latin America
4.4.5. Middle East
4.4.5.1. Saudi Arabia
4.5. Pricing Analysis
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Suppliers
4.6.2. Bargaining Power of Buyers
4.6.3. Threat of Substitutes
4.6.4. Threat of New Entrants
4.6.5. Degree of Competition
5. Microfluidic Immunoassay Market Assessment—by Product
5.1. Overview
5.2. Consumables
5.2.1. Cartridges
5.2.1.1. Polymer
5.2.1.2. Glass
5.2.1.3. Silicon
5.2.2. Reagents
5.3. Systems
6. Microfluidic Immunoassay Market Assessment—by Technology
6.1. Overview
6.2. Electrochemical Detection
6.3. Optical Detection
7. Microfluidic Immunoassay Market Assessment—by Application
7.1. Overview
7.2. Cardiology
7.2.1. Single Biomarker Detection
7.2.2. Multiplexed Biomarker Detection
7.3. Infectious Diseases
7.4. Oncology
7.5. Other Applications
8. Microfluidic Immunoassay Market Assessment—by End User
8.1. Overview
8.2. Pharmaceutical & Biotechnology Companies
8.3. Diagnostic Laboratories
8.4. Hospital
8.5. Other End Users
9. Microfluidic Immunoassay Market Assessment—by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia-Pacific
9.5. Latin America
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
11. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, and Strategic Developments)
11.1. Abbott Laboratories
11.2. Revvity, Inc. (Formerly PerkinElmer, Inc.)
11.3. Siemens Healthineers AG.
11.4. QuidelOrtho Corporation.
11.5. Nanomix, Inc.
11.6. Becton, Dickinson and Company
11.7. Micropoint Biotechnologies Co., Ltd.
11.8. Biosurfit SA
11.9. Koninklijke Philips N.V.
11.10. NanoEnTek Inc.
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Funding for Microfluidic Immunoassay Research & Development
Table 2 Estimated Number of New Cancer Cases, by Type (2020 Vs. 2030)
Table 3 Research Studies on Paper-Based Microfluidics, 2017–2023
Table 4 Authorities Regulating In Vitro Diagnostic Products, by Country/Region
Table 5 Medical Devices Regulatory Authorities in the Rest of APAC Countries
Table 6 Average Selling Prices of Microfluidic Immunoassay Products (USD/Unit)
Table 7 Quidelortho Corporation (U.S.): Product Pricing (USD/Unit)
Table 8 Abbott Laboratories (U.S.): Product Pricing (USD/Unit)
Table 9 Global Microfluidic Immunoassay Market, by Product, 2022-2031 (USD Million)
Table 10 Global Microfluidic Immunoassay Consumables Market, by Type, 2022-2031 (USD Million)
Table 11 Global Microfluidic Immunoassay Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 12 Global Microfluidic Immunoassay Cartridges Market, by Material, 2022-2031 (USD Million)
Table 13 Global Microfluidic Immunoassay Cartridges Market, by Country/Region, 2022–2031 (USD Million)
Table 14 Global Polymer-Based Microfluidic Immunoassay Cartridges Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Glass-Based Microfluidic Immunoassay Cartridges Market, by Country/Region, 2022–2031 (USD Million)
Table 16 Global Silicon-Based Microfluidic Immunoassay Cartridges Market, by Country/Region, 2022–2031 (USD Million)
Table 17 Global Microfluidic Immunoassay Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 18 Global Microfluidic Immunoassay Systems Market, by Country/Region, 2022–2031 (USD Million)
Table 19 Global Microfluidic Immunoassay Market, by Technology, 2022-2031 (USD Million)
Table 20 Global Microfluidic Immunoassay Market for Electrochemical Detection, by Country/Region, 2022–2031 (USD Million)
Table 21 Optical Detection Techniques for Microfluidic Applications
Table 22 Global Microfluidic Immunoassay Market for Optical Detection, by Country/Region, 2022–2031 (USD Million)
Table 23 Global Microfluidic Immunoassay Market, by Application, 2022-2031 (USD Million)
Table 24 Clinically Significant Cardiac Biomarkers
Table 25 Global Microfluidic Immunoassay Market for Cardiology, by Type, 2022-2031 (USD Million)
Table 26 Global Microfluidic Immunoassay Market for Cardiology, by Country/Region, 2022–2031 (USD Million)
Table 27 Commercially Available Tests for Single Cardiac Biomarker Detection
Table 28 Global Microfluidic Immunoassay Market for Single Biomarker Detection, by Country/Region, 2022–2031 (USD Million)
Table 29 Commercially Available Tests for Multiplexed Cardiac Biomarker Detection
Table 30 Global Microfluidic Immunoassay Market for Multiplexed Biomarker Detection, by Country/Region, 2022–2031 (USD Million)
Table 31 Global Microfluidic Immunoassay Market for Infectious Disease, by Country/Region, 2022–2031 (USD Million)
Table 32 Clinically Significant Oncology Biomarkers
Table 33 Global Microfluidic Immunoassay Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 34 Commercially Available Tests for Diabetes Biomarker Detection
Table 35 Global Microfluidic Immunoassay Market for Other Applications, by Country/Region, 2022–2031 (USD Million)
Table 36 Global Microfluidic Immunoassay Market, by End User, 2022-2031 (USD Million)
Table 37 Global Microfluidic Immunoassay Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 38 Global Microfluidic Immunoassay Market for Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 39 Global Microfluidic Immunoassay Market for Hospitals, by Country/Region, 2022–2031 (USD Million)
Table 40 Global Microfluidic Immunoassay Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 41 Global Microfluidic Immunoassay Market, by Country/Region, 2022-2031 (USD Million)
Table 42 North America: Microfluidic Immunoassay Market, by Country, 2022–2031 (USD Million)
Table 43 North America: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 44 North America: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 45 North America: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 46 North America: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 47 North America: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 48 North America: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 49 North America: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 50 U.S.: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 51 U.S.: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 52 U.S.: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 53 U.S.: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 54 U.S.: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 55 U.S.: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 56 U.S.: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 57 Canada: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 58 Canada: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 59 Canada: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 60 Canada: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 61 Canada: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 62 Canada: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 63 Canada: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 64 Europe: Microfluidic Immunoassay Market, by Country/Region, 2022–2031 (USD Million
Table 65 Europe: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 66 Europe: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 67 Europe: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 68 Europe: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 69 Europe: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 70 Europe: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 71 Europe: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 72 Germany: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 73 Germany: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 74 Germany: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 75 Germany: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million
Table 76 Germany: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 77 Germany: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 78 Germany: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 79 France: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 80 France: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 81 France: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 82 France: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 83 France: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 84 France: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 85 France: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 86 U.K.: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 87 U.K.: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 88 U.K.: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 89 U.K.: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 90 U.K.: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 91 U.K.: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 92 U.K.: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 93 Italy: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 94 Italy: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 95 Italy: Microfluidic Immunoassay Cartridges Market, by Material, 2022-2031 (USD Million)
Table 96 Italy: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 97 Italy: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 98 Italy: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 99 Spain: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 100 Spain: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 101 Spain: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 102 Spain: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 103 Spain: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 104 Spain: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 105 Spain: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 106 Covid-19 Cases in European Countries
Table 107 Rest of Europe: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 108 Rest of Europe: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 109 Rest of Europe: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 110 Rest of Europe: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 111 Rest of Europe: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 112 Rest of Europe: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 113 Rest of Europe: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 114 Asia-Pacific: Microfluidic Immunoassay Market, by Country/Region, 2022–2031 (USD Million)
Table 115 Asia-Pacific: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 116 Asia-Pacific: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 117 Asia-Pacific: Microfluidic Immunoassay Cartridges Market, by Material,2022–2031 (USD Million)
Table 118 Asia-Pacific: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 119 Asia-Pacific: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 120 Asia-Pacific: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 121 Asia-Pacific: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 122 China: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 123 China: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 124 China: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 125 China: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 126 China: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 127 China: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 128 China: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 129 Japan: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 130 Japan: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 131 Japan: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 132 Japan: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 133 Japan: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 134 Japan: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 135 Japan: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 136 India: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 137 India: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 138 India: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 139 India: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 140 India: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 141 India: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 142 India: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 143 Rest of Asia-Pacific: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 144 Rest of Asia-Pacific: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 145 Rest of Asia-Pacific: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 146 Rest of Asia-Pacific: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 147 Rest of Asia-Pacific: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 148 Rest of Asia-Pacific: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 149 Rest of Asia-Pacific: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 150 Latin America: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 151 Latin America: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 152 Latin America: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 153 Latin America: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 154 Latin America: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 155 Latin America: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 156 Latin America: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 157 Saudi Arabia, South Africa, and UAE Estimated Cancer Incidence
Table 158 Middle East & Africa: Microfluidic Immunoassay Market, by Product, 2022–2031 (USD Million)
Table 159 Middle East & Africa: Microfluidic Immunoassay Consumables Market, by Type, 2022–2031 (USD Million)
Table 160 Middle East & Africa: Microfluidic Immunoassay Cartridges Market, by Material, 2022–2031 (USD Million)
Table 161 Middle East & Africa: Microfluidic Immunoassay Market, by Technology, 2022–2031 (USD Million)
Table 162 Middle East & Africa: Microfluidic Immunoassay Market, by Application, 2022–2031 (USD Million)
Table 163 Middle East & Africa: Microfluidic Immunoassay Market for Cardiology, by Type, 2022–2031 (USD Million)
Table 164 Middle East & Africa: Microfluidic Immunoassay Market, by End User, 2022–2031 (USD Million)
Table 165 Recent Developments, by Company, 2020–2024
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Microfluidic Immunoassay Market, by Product, 2024 Vs. 2031 (USD Million)
Figure 8 Global Microfluidic Immunoassay Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 9 Global Microfluidic Immunoassay Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 10 Global Microfluidic Immunoassay Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 11 Microfluidic Immunoassay Market, by Geography
Figure 12 Impact Analysis of Market Dynamics
Figure 13 Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion)
Figure 14 Eu Regulatory Pathway - IVDR 2017/746
Figure 15 Porter’s Five Forces Analysis
Figure 16 Global Microfluidic Immunoassay Market, by Product, 2024 Vs. 2031 (USD Million)
Figure 17 Global Microfluidic Immunoassay Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 18 Global Microfluidic Immunoassay Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 19 Global Microfluidic Immunoassay Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 20 Global Pharmaceutical R&D Spending, 2012–2026 (USD Billion)
Figure 21 Global Microfluidic Immunoassay Market, by Region, 2024 Vs. 2031 (USD Million)
Figure 22 North America: Number of People Aged 65 Years and Above, 2015–2021 (In Million)
Figure 23 North America: Microfluidic Immunoassay Market Snapshot
Figure 24 U.S.: Pharmaceutical R&D Expenditure, 2014–2021 (USD Billion)
Figure 25 Europe: Pharmaceutical Industry R&D Expenditure, 2000–2021 (USD Million)
Figure 26 Europe: Microfluidic Immunoassay Market Snapshot
Figure 27 U.K: Estimated Number of Cancer Cases, 2020–2030
Figure 28 Pharmaceutical R&D Expenditure, by Country, 2020 (USD Million)
Figure 29 Asia-Pacific: Microfluidic Immunoassay Market Snapshot
Figure 30 Key Growth Strategies Adopted by Leading Players, 2020–2024
Figure 31 Microfluidic Immunoassay Market: Competitive Benchmarking (Based on Product)
Figure 32 Microfluidic Immunoassay Market: Competitive Benchmarking (Based on Geography)
Figure 33 Competitive Dashboard: Microfluidic Immunoassay Market
Figure 34 Abbott Laboratories: Financial Overview (2023)
Figure 35 PerkinElmer, Inc.: Financial Overview (2023)
Figure 36 Siemens Healthineers AG: Financial Overview (2023)
Figure 37 QuidelOrtho Corporation: Financial Snapshot (2023)
Figure 38 Nanomix, Inc.: Financial Overview (2023)
Figure 39 Becton, Dickinson and Company: Financial Overview (2023)
Figure 40 Koninklijke Philips N.V.: Financial Snapshot (2023)
Figure 41 NanoEnTek Inc.: Financial Snapshot (2023)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Jan-2024
Published Date: May-2023
Published Date: Jul-2020
Published Date: Aug-2023
